Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Healthy
Interventions: Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo; Drug · Other
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Acetabulum Fractures
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Overweight, Obesity
Interventions: NNC0247-0829, Placebo (NNC0247-0829); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: BI201335, PegIFN/RBV, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 78
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more

Conditions: Menopause
Interventions: DR-2041a, DR-2041b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 97
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more

Conditions: West Nile Fever Encephalitis
Interventions: WN/DEN4-3'delta30, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Nashville, Tennessee

Conditions: Healthy Subjects
Interventions: placebo, lorazepam, GW876008; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Kidney Transplantation
Interventions: TAP block, liposomal bupivacaine plus free bupivacaine, normal saline; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Schizophrenia
Interventions: OPC-34712, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 19
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 15 more

Conditions: Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions: onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Nonalcoholic Steatohapatitis
Interventions: Roflumilast, Pioglitazone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Coronado, California • Annapolis, Maryland • Baltimore, Maryland

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: afatinib, placebo; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 272
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more

Conditions: Ulcerative Colitis (UC)
Interventions: Mesalamine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions: erlotinib hydrochloride, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 20
States / cities: Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more

Conditions: Bipolar II Disorder
Interventions: Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 19 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Prehypertension, Hypertension
Interventions: Sleep Enhancement, Health Education; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Skin Irritation
Interventions: 4 placebo, 4 Vitamin D, Valchlor; Dietary Supplement · Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioblastoma
Interventions: Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Female Sexual Dysfunction
Interventions: percutaneous tibial nerve stimulation (PTNS), Sham procedure; Device
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Mammographic Breast Density
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions: Peanut powder, Peanut extract, Placebo extract, Placebo powder; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anorexia Nervosa, Eating Disorders
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

Does an Abdominal Wall Nerve Block During Surgery Help Reduce Pain From Kidney Transplantation?

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Erlotinib for Hepatocellular Carcinoma Chemoprevention

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Differential Responses to Drugs and Sweet Tastes

HELP-HY: Health Education and sLeep Program in HYpertension

Effect of Vitamin D After Application With Valchlor

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa